Nasdaq:US$13.40 (+0.13) | HKEX:HK$21.30 (+0.25) | AIM:£2.08 (-0.01)
Search Result
Previous Article   |   Next Article
Scientific Publications | 3 Nov 2021

NANETS 2021: Interim Analysis Results of Surufatinib in US Patients with Neuroendocrine Tumors